Literature DB >> 9045958

CD44H plays an important role in peritoneal dissemination of scirrhous gastric cancer cells.

S Nishimura1, Y S Chung, M Yashiro, T Inoue, M Sowa.   

Abstract

The role of the adhesion molecule CD44H in the peritoneal adhesion and invasion of cancer cells was assessed using cell lines with low and high peritoneal seeding ability, OCUM-2M (2M) and OCUM-2MD3 (2MD3), respectively. The in vitro binding ability to peritoneal components (mesothelial cells, fibronectin and type I collagen) and invasive ability of 2MD3 cells were higher than those of 2M cells. The expression level of CD44H on 2MD3 cells was higher than that on 2M cells as determined by western blot analysis and flow cytometry. The adhesiveness of 2MD3 cells to hyaluronic acid, which is expressed on the surfaces of mesothelial cells, was greater than that of 2M cells. The binding ability of 2MD3 cells to mesothelial cells was inhibited in the presence of anti-CD44H monoclonal antibody, but that of 2M cells was not. These results suggested that the 2MD3 cell binding to mesothelial cells is regulated by the CD44-hyaluronic acid dependent system. The in vitro binding to submesothelial components and the invasiveness of 2MD3 cells were also inhibited in the presence of anti-CD44H antiody. The in vivo inoculation of 2MD3 cells treated with an anti-CD44H antibody resulted in a significiant prolongation of survival time as compared with control mice that were inoculated with 2MD3 cells alone. In conclusion, CD44H was associated with attachment not only to hyaluronic acid on mesothelial cells, but also to peritoneal stromal components. Thus, CD44H may play an important role in cancer cell binding and invasion in the peritoneal dissemination of scirrhous gastric cancer cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9045958      PMCID: PMC5921032          DOI: 10.1111/j.1349-7006.1996.tb03138.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  31 in total

1.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

2.  Morphogenesis of peritoneal metastasis in human gastric cancer.

Authors:  Y Kiyasu; S Kaneshima; S Koga
Journal:  Cancer Res       Date:  1981-03       Impact factor: 12.701

3.  Expression of CD44R1 adhesion molecule in colon carcinomas and metastases.

Authors:  K K Tanabe; L M Ellis; H Saya
Journal:  Lancet       Date:  1993-03-20       Impact factor: 79.321

4.  Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H.

Authors:  S A Cannistra; G S Kansas; J Niloff; B DeFranzo; Y Kim; C Ottensmeier
Journal:  Cancer Res       Date:  1993-08-15       Impact factor: 12.701

5.  Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons.

Authors:  G R Screaton; M V Bell; D G Jackson; F B Cornelis; U Gerth; J I Bell
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

6.  CD44 mediates human glioma cell adhesion and invasion in vitro.

Authors:  A Merzak; S Koocheckpour; G J Pilkington
Journal:  Cancer Res       Date:  1994-08-01       Impact factor: 12.701

7.  B lymphocyte fibronectin receptors: expression and utilization.

Authors:  D G Stupack; S Stewart; W G Carter; E A Wayner; J A Wilkins
Journal:  Scand J Immunol       Date:  1991-12       Impact factor: 3.487

8.  The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells.

Authors:  I Stamenkovic; A Aruffo; M Amiot; B Seed
Journal:  EMBO J       Date:  1991-02       Impact factor: 11.598

9.  A human homologue of the rat metastasis-associated variant of CD44 is expressed in colorectal carcinomas and adenomatous polyps.

Authors:  K H Heider; M Hofmann; E Hors; F van den Berg; H Ponta; P Herrlich; S T Pals
Journal:  J Cell Biol       Date:  1993-01       Impact factor: 10.539

10.  CD44H regulates tumor cell migration on hyaluronate-coated substrate.

Authors:  L Thomas; H R Byers; J Vink; I Stamenkovic
Journal:  J Cell Biol       Date:  1992-08       Impact factor: 10.539

View more
  15 in total

1.  A three-dimensional in-vitro model for the study of peritoneal tumour metastasis.

Authors:  D G Jayne; R O'Leary; A Gill; A Hick; P J Guillou
Journal:  Clin Exp Metastasis       Date:  1999       Impact factor: 5.150

2.  Enhancement of port site metastasis by hyaluronic acid under CO2 pneumoperitoneum in a murine model.

Authors:  K Yamaguchi; Y Hirabayashi; A Shiromizu; N Shiraishi; Y Adachi; S Kitano
Journal:  Surg Endosc       Date:  2001-02-06       Impact factor: 4.584

3.  VEGF significance in peritoneal recurrence from gastric cancer.

Authors:  Keishiro Aoyagi; Kikuo Kouhuji; Shojiro Yano; Motoshi Miyagi; Takuya Imaizumi; Jinryo Takeda; Kazuo Shirouzu
Journal:  Gastric Cancer       Date:  2005       Impact factor: 7.370

4.  Cancer-stromal interactions in scirrhous gastric carcinoma.

Authors:  Masakazu Yashiro; Kosei Hirakawa
Journal:  Cancer Microenviron       Date:  2010-01-26

Review 5.  The significance of scirrhous gastric cancer cell lines: the molecular characterization using cell lines and mouse models.

Authors:  Masakazu Yashiro; Tasuku Matsuoka; Masaichi Ohira
Journal:  Hum Cell       Date:  2018-06-06       Impact factor: 4.174

6.  Adhesion polypeptides are useful for the prevention of peritoneal dissemination of gastric cancer.

Authors:  T Matsuoka; K Hirakawa; Y S Chung; M Yashiro; S Nishimura; T Sawada; I Saiki; M Sowa
Journal:  Clin Exp Metastasis       Date:  1998-05       Impact factor: 5.150

7.  Port-site metastasis after CO2 pneumoperitoneum: role of adhesion molecules and prevention with antiadhesion molecules.

Authors:  Y Hirabayashi; K Yamaguchi; N Shiraishi; Y Adachi; I Saiki; S Kitano
Journal:  Surg Endosc       Date:  2004-05-12       Impact factor: 4.584

8.  Disruption of the integrity of human peritoneal mesothelium by interleukin-1beta and tumor necrosis factor-alpha.

Authors:  Sylvia Stadlmann; Ruth Raffeiner; Albert Amberger; Raimund Margreiter; Alain Gustave Zeimet; Burkhardt Abendstein; Patrizia Lucia Moser; Gregor Mikuz; Bernd Klosterhalfen; Felix Albert Offner
Journal:  Virchows Arch       Date:  2003-07-26       Impact factor: 4.064

9.  Prognostic Impact of CD44 Expression in Patients With Myxofibrosarcoma.

Authors:  Hiroyuki Tsuchie; Makoto Emori; Naohisa Miyakoshi; Hiroyuki Nagasawa; Kyoji Okada; Hiroshi Nanjyo; Yasutaka Murahashi; Emi Mizushima; Junya Shimizu; Toshihiko Yamashita; Yoichi Shimada
Journal:  In Vivo       Date:  2019 Nov-Dec       Impact factor: 2.155

10.  Increased CD44s and decreased CD44v6 RNA expression are associated with better survival in myxofibrosarcoma patients: a pilot study.

Authors:  Christiane Matuschek; Marcus Lehnhardt; Peter Arne Gerber; Christopher Poremba; Jackson Hamilton; Guido Lammering; Klaus Orth; Wilfried Budach; Hans Bojar; Edwin Bölke; Matthias Peiper
Journal:  Eur J Med Res       Date:  2014-02-03       Impact factor: 2.175

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.